Loading
companiesCompany
Teclison
Teclison is a US-based biotechnology company that leads 3 cancer trials in OnCo, testing trans-arterial tirapazamine embolisation (TATE) in hepatocellular carcinoma, neuroendocrine tumours and colorectal cancer.
Also called: Teclison Ltd.
Overview
Teclison develops cancer therapies designed to induce tumour necrosis and enhance anti-tumour immunity, with a focus on improving the effect of immune checkpoint inhibitors in solid tumours that have spread to the liver. Its clinical programme is trans-arterial tirapazamine embolisation (TATE), studied alone and with pembrolizumab. It has offices in Princeton and Taipei. On ClinicalTrials.gov it is the lead sponsor of 3 trials recorded in OnCo: NCT03259867 (phase 2, Combination of TATE and PD-1 Inhibitor in Liver Cancer), NCT02174549 (phase 1/2, Dose-defining Study of Tirapazamine Combined With Embolization in Liver Cancer) and NCT04701476 (phase 2, TATE and Pembrolizumab (MK3475) in mCRC and NSCLC). Sponsor and trial facts are from the ClinicalTrials.gov registry; company facts are from the official website.
Headquarters
Princeton, New Jersey, US
Scorecard
All companies#27of 1244 companies, score 95
- approved products +24
- targets +8
- modalities +6
- regions +7
- 24-month regulatory events +20
- registry trials +30
4 approved, 0 in phase 3, 0 earlier, 4 targets, 3,809 registry studies. Formula on the scorecards page.
Type
Stage
Growth stage
Website
ApprovedMonoclonal antibody (anti-PD-1)
Nivolumab · Opdivo / Opdivo Qvantig (SC)
Nivolumab was the second PD-1 blocker and is often combined with ipilimumab. Long-term data show about half of advanced melanoma patients alive at 10 years on the combination.
ApprovedMonoclonal antibody (anti-PD-1)
Pembrolizumab · Keytruda / Keytruda Qlex (SC)
Pembrolizumab is a PD-1 blocking antibody approved in more than 40 settings, from melanoma and lung cancer to the first tumour-agnostic approval for mismatch-repair-deficient tumours in 2017, and before and after surgery in triple-negative breast cancer. A subcutaneous form arrived in 2025, and it is the backbone partner for ADCs and personalised neoantigen vaccines.
ApprovedCytotoxic chemotherapy (oral nucleoside)
Trifluridine/tipiracil · Lonsurf
An oral chemotherapy pill for bowel cancer that has stopped responding to everything else; with bevacizumab it extends life by about three months.
ApprovedSmall-molecule multi-kinase inhibitor
Regorafenib · Stivarga
A sorafenib successor that became the first second-line drug proven to prolong life in liver cancer (2017).
Similar pages
- TermColorectal cancer drugs in England: what NICE has recommended
Shares Trifluridine/tipiracil, Regorafenib, Nivolumab, Pembrolizumab.
- TrialInjection of SHR-A1811 Versus Physician Choiced Treatment in Patients With Advanced Colorectal Cancer Who Had Failed to Respond to Oxaliplatin, 5-fu,
Shares Trifluridine/tipiracil, Regorafenib, Colorectal cancer.
- TrialSafety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis
Shares Regorafenib, Nivolumab, Pembrolizumab, Colorectal cancer.
- TargetCRAF (RAF1)
Shares Regorafenib, Hepatocellular carcinoma, Colorectal cancer.
- TargetTIE2 receptor (TEK)
Shares Regorafenib, Hepatocellular carcinoma, Colorectal cancer.
- TrialFOG-001 in Locally Advanced or Metastatic Solid Tumors
Shares Trifluridine/tipiracil, Nivolumab, Colorectal cancer.
- TrialA Phase Ib/III Study of Suvemcitug Plus FTD/TPI in Participants With Refractory Metastatic Colorectal Cancer
Shares Trifluridine/tipiracil, Colorectal cancer.
- Trial5-Fluorouracil/Leucovorin (5FU/LV) in Combination With Regorafenib in Patients With Metastatic Colorectal Cancer
Shares Trifluridine/tipiracil, Regorafenib.
cancers
drugs
ApprovedMonoclonal antibody (anti-PD-1)
Nivolumab · Opdivo / Opdivo Qvantig (SC)
ApprovedMonoclonal antibody (anti-PD-1)
Pembrolizumab · Keytruda / Keytruda Qlex (SC)
ApprovedSmall-molecule multi-kinase inhibitor
Regorafenib · Stivarga
ApprovedCytotoxic chemotherapy (oral nucleoside)
Trifluridine/tipiracil · Lonsurf